Rigel Pharmaceuticals
RIGL
108 hedge funds and large institutions have $278M invested in Rigel Pharmaceuticals in 2017 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 11 closing their positions.
282% more call options, than puts
Call options by funds: $401K | Put options by funds: $105K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
0.17% less ownership
Funds ownership: 8.94% → 8.77% (-0.17%)
2% less funds holding
Funds holding: 110 → 108 (-2)
7% less capital invested
Capital invested by funds: $299M → $278M (-$21.2M)
18% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$2.37M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$2.22M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$1.69M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.02M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
+$979K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$5.35M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.2M |
| 3 |
PC
Paulson & Co
New York
|
-$1.81M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.04M |
| 5 |
BlackRock
New York
|
-$909K |
RIGL Hedge Fund Activity: Q3 2017 in Review
108 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2017, worth a combined $278M — down 7.1% from $299M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RIGL and 9 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 36 added.
The largest buyer was Rhenman & Partners Asset Management, adding an estimated $2.37M. The largest seller was Millennium Management, cutting an estimated $5.35M.
- 108 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2017, down from 110 in Q2 2017.
- Funds reported $278M of Rigel Pharmaceuticals stock for Q3 2017, down 7.1% quarter-over-quarter.
- 9 funds opened new Rigel Pharmaceuticals positions in Q3 2017 and 11 closed out, a net change of -2 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2017 was Rhenman & Partners Asset Management, an estimated $2.37M added.
- The largest Rigel Pharmaceuticals seller in Q3 2017 was Millennium Management, an estimated $5.35M sold.
Based on aggregated 13F filings for Q3 2017.